- Start
- Nov 20, 202590% CONFIDENCEfrom the source
Abbott Agrees to Buy Exact Sciences for $21 Billion
- Abbott and Exact Sciences announced a definitive agreement for Abbott to buy all Exact Sciences shares for $105 each in cash, a total equity value of about $21 billion and an estimated enterprise value of $23 billion, with Abbott absorbing about $1.8 billion of Exact Sciences' net debt[1]
- The merger agreement was signed on 19 November 2025, and closing needs a majority vote of Exact Sciences stockholders and the end of the Hart-Scott-Rodino waiting period; Abbott expected to close in the second quarter of 2026[1][3]
- The price was a 51% premium to Exact Sciences' $69.68 close on 18 November, the day before Bloomberg reported the talks, and it was Abbott's largest acquisition in a decade; Abbott shares fell 1.7% that morning[5]
- Exact Sciences was projected to post more than $3 billion of 2025 revenue and brings the Cologuard stool test, Oncotype DX for breast cancer, the Oncodetect residual-disease test and the Cancerguard multi-cancer blood test; Abbott's diagnostics sales would pass $12 billion a year[1]
- Abbott put the U.S. cancer screening and precision oncology diagnostics segments at $60 billion, and it was the largest medtech deal announced that year[2][4]
- Exact Sciences was to keep its presence in Madison, Wisconsin, with chief executive Kevin Conroy staying on in an advisory role[1]
References 586% CONFIDENCE
The first entry is always the pin's source. Overall confidence is a weighted average of how firmly each reference supports the start and end times used above; a reference counts half as much for every 180 days older than the newest.
- [1]90%abbott.mediaroom.com/2025-11-20-Abbott-to-acquire-Exact-Sciences,-a-leader-in-large-and-fast-growing-cancer-screening-and-precision-oncology-diagnostics-segmentsabbott.mediaroom.com· Posted Sep 23, 2026· Starts Nov 20, 2025 ✓· 45% of score
The release is datelined "ABBOTT PARK, Ill., and MADISON, Wis., Nov. 20, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) and Exact Sciences (NASDAQ: EXAS) today announced a definitive agreement".
- [2]76%Abbott's $21B Exact Sciences buy reveals future strategymedtechdive.com· Published Nov 21, 2025· 14% of score
MedTech Dive[4] analyst round-up: the largest medtech deal of the year and the largest under chief executive Robert Ford, about $100 million of pre-tax synergies expected by 2028.
- [3]92%Abbott Laboratories Form 8-K: Agreement and Plan of Merger with Exact Sciencessec.gov· Published Nov 20, 2025· 14% of score
Abbott's 8-K: the merger agreement was signed on 19 November 2025 at $105.00 in cash per share, conditional on Exact Sciences stockholder adoption and the Hart-Scott-Rodino waiting period.[1]
- [4]85%Abbott to acquire Exact Sciences for about $21Bmedtechdive.com· Published Nov 20, 2025· 14% of score
MedTech Dive's[2] same-day report: $105 a share, $1.8 billion of debt absorbed, the $60 billion segment by Abbott's estimate, and the year's largest medtech deal.
- [5]80%Abbott Laboratories announces $21 billion deal to buy Cologuard-maker Exact Sciences (Chicago Tribune)finance.yahoo.com· Published Nov 20, 2025· 14% of score
Chicago Tribune: a 51% premium to the $69.68 close on 18 November, Abbott's largest acquisition in a decade, and a 1.7% fall in Abbott shares that morning.[1]
Suggest a correction
Something missing or wrong? Say it in your own words: a link that backs this pin up, a different start or end date and why, or a fact it lacks or gets wrong. The AI checks it against this pin's sources, searches for better ones, and adds any page that backs you up. The pin's own sources still count most.
Amazon
